

09/445517

METHODS FOR TREATING OBESITY

1 This application is a continuation-in-part of U.S.
5 Patent Application Serial No. 08/870,762, filed June 6, 1997,
the contents of which is hereby incorporated by reference in
its entirety.

Field of the Invention

10 The present invention relates to methods for
treating obesity. More particularly, the invention relates
to the use of an amylin or agonist of amylin in the treatment
of obesity.

BackgroundAmylin

15 The structure and biology of amylin have previously
been reviewed. See, for example, Rink et al., *Trends in
Pharmaceutical Sciences*, 14:113-118 (1993); Gaeta and Rink,
20 *Med. Chem. Res.*, 3:483-490 (1994); and, Pittner et al., *J.
Cell. Biochem.*, 55S:19-28 (1994). Amylin is a 37 amino acid
protein hormone. It was isolated, purified and chemically
characterized as the major component of amyloid deposits in
the islets of pancreases of deceased human Type 2 diabetics
25 (Cooper et al., *Proc. Natl. Acad. Sci. USA*, 84:8628-8632
(1987)). The amylin molecule has two important post-
translational modifications: the C-terminus is amidated
(i.e., the 37th amino acid residue is tyrosinamide), and the
cysteines in positions 2 and 7 are cross-linked to form an N-
30 terminal loop (via a cystine residue). The sequence of the
open reading frame of the human amylin gene shows the

presence of the Lys-Arg dibasic amino acid proteolytic cleavage signal, prior to the N-terminal codon for Lys, and the Gly prior to the Lys-Arg proteolytic signal at the C-terminal position, a typical sequence for amidation by protein amidating enzyme, PAM (Cooper *et al.*, *Biochem. Biophys. Acta*, 1014:247-258 (1989)). Amylin is described and claimed in United States Patent No. 5,367,052, issued November 22, 1994.

In Type 1 diabetes, amylin has been shown to be deficient and combined replacement with insulin has been proposed as a preferred treatment over insulin alone in all forms of diabetes. The use of amylin and other amylin agonists for the treatment of diabetes mellitus is the subject of United States Patent No. 5,175,145, issued December 29, 1992. Pharmaceutical compositions containing amylin and amylin plus insulin are described and claimed in United States Patent No. 5,124,314, issued June 23, 1992.

Excess amylin action has been said to mimic key features of Type 2 diabetes and amylin blockade has been proposed as a novel therapeutic strategy. It has been disclosed in United States Patent No. 5,266,561, issued November 30, 1993, that amylin causes reduction in both basal and insulin-stimulated incorporation of labeled glucose into glycogen in skeletal muscle. The latter effect was also disclosed to be shared by calcitonin gene related peptide (CGRP) (see also Leighton and Cooper, *Nature*, 335:632-635 (1988)). Amylin is also reported to reduce insulin-stimulated uptake of glucose into skeletal muscle and reduce glycogen content (Young *et al.*, *Amer. J. Physiol.*, 259:45746-

1 (1990)). The treatment of Type 2 diabetes and insulin resistance with amylin antagonists is disclosed.

The sequence of amylin is about 50% homologous to the CGRPs, also 37 amino acid proteins which are widespread neurotransmitters with many potent-biological actions, including vasodilation. Amylin and CGRP share the ³Cys-⁷Cys disulphide bridge and a C-terminal amino acid amide residue, both of which are essential for full biologic activity (Cooper et al., *Proc. Natl. Acad. Sci. USA*, 857763-7766 (1988)). Amylin reportedly may be one member of a family of related peptides which includes CGRP, insulin, insulin-like growth factors and the relaxins and which share common genetic heritage (Cooper et al., *Prog. Growth Factor Research*, 1:99-105 (1989)).

Amylin is primarily synthesized in pancreatic beta cells and is secreted in response to nutrient stimuli such as glucose and arginine. Studies with cloned beta-cell tumor lines (Moore et al., *Biochem. Biophys. Res. Commun.*, 179(1) (1991)), have shown that nutrient secretagogues such as glucose and arginine stimulate release of amylin as well as insulin. The molar amylin:insulin ratio of the secreted proteins varies between preparations from about 0.01 to 0.4, but appears not to vary much with acute stimuli in any one preparation. However, during prolonged stimulation by elevated glucose, the amylin:insulin ratio can progressively increase (Gedulin et al., *Biochem. Biophys. Res. Commun.*, 180(1):782-789 (1991)). Thus, amylin and insulin are not always secreted in a constant ratio.

It has been discovered and reported that certain actions of amylin are similar to some non-metabolic actions

of CGRP and calcitonin; however, the metabolic actions of amylin discovered during investigations of this newly identified protein appear to reflect its primary biologic role. At least some of these metabolic actions are mimicked by CGRP, albeit at doses which are markedly vasodilatory (see, e.g., Leighton et al., *Nature*, 335:632-635 (1988)); Molina et al., *Diabetes*, 39:260-265 (1990)).

The first discovered action of amylin was the reduction of insulin-stimulated incorporation of glucose into glycogen in rat skeletal muscle (Leighton et al., *Nature*, 335:632-635 (1988)); the muscle was made "insulin-resistant." Subsequent work with rat soleus muscle *ex-vivo* and *in vitro* has indicated that amylin reduces glycogen synthase activity, promotes conversion of glycogen phosphorylase from the inactive b form to the active a form, promotes net loss of glycogen (in the presence or absence of insulin), increases glucose-6-phosphate levels, and can increase lactate output (see, e.g., Deems et al., *Biochem. Biophys. Res. Commun.*, 181(1):116-120 (1991)); Young et al., *FEBS Letts*, 281(1,2):149-151 (1991)). Amylin appears not to affect glucose transport per se (e.g., Pittner et al., *FEBS Letts*, 365(1):98-100 (1995)). Studies of amylin and insulin dose-response relations show that amylin acts as a noncompetitive or functional antagonist of insulin in skeletal muscle (Young et al., *Am. J. Physiol.*, 263(2):E274-E281 (1992)). There is no evidence that amylin interferes with insulin binding to its receptors, or the subsequent activation of insulin receptor tyrosine kinase (Follett et al., *Clinical Research*, 39(1):39A (1991)); Koopmans et al., *Diabetologia*, 34:218-224 (1991)).

It is believed that amylin acts through receptors present in plasma membranes. Studies of amylin and CGRP, and the effect of selective antagonists, suggest that amylin acts via its own receptor (Beaumont et al., *Br. J. Pharmacol.*, 115(5):713-715 (1995); Wang et al., *FEBS Letts.*, 219:195-198 (1991 b)), counter to the conclusion of other workers that amylin may act primarily at CGRP receptors (e.g., Chantry et al., *Biochem. J.*, 277:139-143 (1991)); Galeazza et al., *Peptides*, 12:585-591 (1991)); Zhu et al., *Biochem. Biophys. Res. Commun.*, 177(2):771-776 (1991)). Amylin receptors and their use in methods for screening and assaying for amylin agonist and antagonist compounds are described in United States Patent No. 5,264,372, issued November 23, 1993.

While amylin has marked effects on hepatic fuel metabolism *in vivo*, there is no general agreement as to what amylin actions are seen in isolated hepatocytes or perfused liver. The available data do not support the idea that amylin promotes hepatic glycogenolysis, i.e., it does not act like glucagon (e.g., Stephens et al., *Diabetes*, 40:395-400 (1991); Gomez-Foix et al., *Biochem J.*, 276:607-610 (1991)). It has been suggested that amylin may act on the liver to promote conversion of lactate to glycogen and to enhance the amount of glucose able to be liberated by glucagon (see Roden et al., *Diabetologia*, 35:116-120 (1992)). In this way, amylin could act as an anabolic partner to insulin in liver, in contrast to its catabolic action in muscle.

In fat cells, contrary to its action in muscle, amylin has no detectable actions on insulin-stimulated glucose uptake, incorporation of glucose into triglyceride, CO₂ production (Cooper et al., *Proc. Natl. Acad. Sci.*,

85:7763-7766 (1988)) epinephrine-stimulated lipolysis, or insulin-inhibition of lipolysis (Lupien and Young, "Diabetes Nutrition and Metabolism - Clinical and Experimental," Vol. 6(1), pages 1318 (February 1993)). Amylin thus exerts
5 tissue-specific effects, with direct action on skeletal muscle, marked indirect (via supply of substrate) and perhaps direct effects on liver, while adipocytes appear "blind" to the presence or absence of amylin.

It has also been reported that amylin can have
10 marked effects on secretion of insulin. Experiments in the intact rat (Young *et al.*, *Mol. Cell. Endocrinol.*, 84:R1-R5 (1992)) indicate that amylin inhibits insulin secretion. Other workers, however, have been unable to detect effects of amylin on isolated β -cells, on isolated islets, or in the
15 whole animal (see Broderick *et al.*, *Biochem. Biophys. Res. Commun.*, 177:932-938 (1991)).

Amylin or amylin agonists potently inhibit gastric emptying in rats (Young *et al.*, *Diabetologia* 38(6):642-648 (1995)), dogs (Brown *et al.*, *Diabetes* 43(Suppl 1):172A
20 (1994)) and humans (Macdonald *et al.*, *Diabetologia* 38(Suppl 1):A32 (abstract 118) (1995)). Gastric emptying is reportedly accelerated in amylin-deficient type 1 diabetic BB rats (Young *et al.*, *Diabetologia*, *supra*; Nowak *et al.*, *J. Lab. Clin. Med.*, 123(1):110-6 (1994)) and in rats treated with the
25 selective amylin antagonist, AC187 (Gedulin *et al.*, *Diabetologia*, 38(Suppl 1):A244 (1995)). The effect of amylin on gastric emptying appears to be physiological (operative at concentrations that normally circulate).

Non-metabolic actions of amylin include vasodilator
30 effects which may be mediated by interaction with CGRP

vascular receptors. Reported *in vivo* tests suggest that amylin is at least about 100 to 1000 times less potent than CGRP as a vasodilator (Brain et al., *Eur. J. Pharmacol.*, 183:2221 (1990); Wang et al., *FEBS Letts.*, 291:195-198 (1991)). The effect of amylin on regional hemodynamic actions, including renal blood flow, in conscious rats has been reported (Gardiner et al., *Diabetes*, 40:948-951 (1991)). The authors noted that infusion of rat amylin was associated with greater renal vasodilation and less mesenteric vasoconstriction than is seen with infusion of human α -CGRP. They concluded that, by promoting renal hyperemia to a greater extent than did α -CGRP, rat amylin could cause less marked stimulation of the renin-angiotensin system, and thus, less secondary angiotensin II-mediated vasoconstriction. It was also noted, however, that during coinfusion of human α -⁸-CGRP and rat amylin, renal and mesenteric vasoconstrictions were unmasked, presumably due to unopposed vasoconstrictor effects of angiotensin II, and that this finding is similar to that seen during coinfusion of human A-CGRP and human α -⁸-CGRP (id. at 951).

Amylin has also been reported to have effects both on isolated osteoclasts where it caused cell quiescence, and *in vivo* where it was reported to lower plasma calcium by up to 20% in rats, in rabbits, and in humans with Paget's disease (see, e.g., Zaidi et al., *Trends in Endocrinol. and Metab.*, 4:255-259 (1993)). From the available data, amylin seems to be 10 to 30 times less potent than human calcitonin for these actions. Interestingly, it was reported that amylin appeared to increase osteoclast cAMP production but not to increase cytosolic Ca^{2+} , while calcitonin does both

(Alam et al., *Biochem. Biophys. Res. Commun.*, 179(1):134-139 (1991)). It was suggested, though not established, that calcitonin may act via two receptor types and that amylin may interact with one of these.

5 It has also been discovered that, surprisingly in view of its previously described renal vasodilator and other properties, amylin markedly increases plasma renin activity in intact rats when given subcutaneously in a manner that avoids any disturbance of blood pressure. This latter point
10 is important because lowered blood pressure is a strong stimulus to renin release. Amylin antagonists, such as amylin receptor antagonists, including those selective for amylin receptors compared to CGRP and/or calcitonin receptors, can be used to block the amylin-evoked rise of
15 plasma renin activity. The use of amylin antagonists to treat renin-related disorders is described and claimed in United States Patent No. 5,376,638, issued December 27, 1994.

In normal humans, fasting amylin levels from 1 to 10pM and post-prandial or post-glucose levels of 5 to 20pM
20 have been reported (e.g., Koda et al., *The Lancet*, 339:1179-1180 (1992)). In obese, insulin-resistant individuals, post-food amylin levels can go higher, reaching up to about 50pM. For comparison, the values for fasting and post-prandial insulin are 20 to 50pM, and 100 to 300 pM respectively in
25 healthy people, with perhaps 3-to 4-fold higher levels in insulin-resistant people. In Type 1 diabetes, where beta cells are destroyed, amylin levels are at or below the levels of detection and do not rise in response to glucose (Koda et al., *The Lancet*, 339:1179-1180 (1992)). In normal mice and
30 rats, basal amylin levels have been reported from 30 to 100

pM, while values up to 600 pM have been measured in certain insulin-resistant, diabetic strains of rodents (e.g., Huang et al., *Hypertension*, 19:I-101-I-109 (1991)).

Injected into the brain, or administered peripherally, amylin has been reported to suppress food intake, e.g., Chance et al., *Brain Res.*, 539:352-354 (1991) and Chance et al., *Brain Res.*, 607:185-188 (1993), an action shared with CGRP and calcitonin. The effective concentrations at the cells that mediate this action are not known. The use of amylin and amylin agonists for the treatment of anorexia is described and claimed in U.S. Patent No. 5,656,590, issued August 12, 1997. Compositions including a cholecystokinin agonist and an amylin agonist or a hybrid molecule for use in reducing food intake or controlling appetite or body weight are disclosed and claimed in U.S. Patent No. 5,739,106, issued April 14, 1998.

Obesity

Obesity is a chronic disease that is highly prevalent in modern society and is associated not only with a social stigma, but also with decreased life span and numerous medical problems, including adverse psychological development, reproductive disorders such as polycystic ovarian disease, dermatological disorders such as infections, varicose veins, Acanthosis nigricans, and eczema, exercise intolerance, diabetes mellitus, insulin resistance, hypertension, hypercholesterolemia, cholelithiasis, osteoarthritis, orthopedic injury, thromboembolic disease, cancer, and coronary heart disease. Rissanen et al., *British Medical Journal*, 301: 835-837 (1990).

Obesity, and especially upper body obesity, is a common and very serious public health problem in the United States and throughout the world. According to recent statistics, more than 25% of the United States population and 27% of the Canadian population are over weight. Kuczmarski, *Amer. J. of Clin. Nut.* 55:495S-502S (1992); Reeder et. al., *Can. Med. Ass. J.*, 23:226-233 (1992). Upper body obesity is the strongest risk factor known for type II diabetes mellitus, and is a strong risk factor for cardiovascular disease and cancer as well. Recent estimates for the medical cost of obesity are \$150,000,000,000 world wide. The problem has become serious enough that the surgeon general has begun an initiative to combat the ever increasing adiposity rampant in American society.

Much of this obesity induced pathology can be attributed to the strong association with dyslipidemia, hypertension, and insulin resistance. Many studies have demonstrated that reduction in obesity by diet and exercise reduces these risk factors dramatically. Unfortunately these treatments are largely unsuccessful with a failure rate reaching 95%. This failure may be due to the fact that the condition is strongly associated with genetically inherited factors that contribute to increased appetite, preference for highly caloric foods, reduced physical activity, and increased lipogenic metabolism. This indicates that people inheriting these genetic traits are prone to becoming obese regardless of their efforts to combat the condition. Therefore, a new pharmacological agent that can correct this adiposity handicap and allow the physician to successfully

treat obese patients in spite of their genetic inheritance is needed.

Existing therapies for obesity include standard diets and exercise, very low calorie diets, behavioral therapy, pharmacotherapy involving appetite suppressants, thermogenic drugs, food absorption inhibitors, mechanical devices such as jaw wiring, waist cords and balloons, and surgery. Jung and Chong, *Clinical Endocrinology*, 35: 11-20 (1991); Bray, *Am. J. Clin. Nutr.*, 55: 538S-544S (1992). Protein-sparing modified fasting has been reported to be effective in weight reduction in adolescents. Lee et al., *Clin. Pediatr.*, 31: 234-236 (April 1992). Caloric restriction as a treatment for obesity causes catabolism of body protein stores and produces negative nitrogen balance. Protein-supplemented diets, therefore, have gained popularity as a means of lessening nitrogen loss during caloric restriction. Because such diets produce only modest nitrogen sparing, a more effective way to preserve lean body mass and protein stores is needed. In addition, treatment of obesity would be improved if such a regimen also resulted in accelerated loss of body fat. Various approaches to such treatment include those discussed by Weintraub and Bray, *Med. Clinics N. Amer.*, 73:237 (1989); Bray, *Nutrition Reviews*, 49:33 (1991).

Considering the high prevalence of obesity in our society and the serious consequences associated therewith as discussed above, any therapeutic drug potentially useful in reducing weight of obese persons could have a profound beneficial effect on their health. There is a need for a drug that will reduce total body weight of obese subjects toward

their ideal body weight and help maintain the reduced weight level.

SUMMARY OF THE INVENTION

5 We have now discovered, surprisingly, that amylin and amylin agonists, for example, the amylin agonist analogue ^{25,28,29}Pro-h-amylin (also referred to as "pramlintide" and previously referred to as "AC-0137"), can be used for treatment of obesity in humans.

10 The present invention is directed to novel methods for treating or preventing obesity in humans comprising the administration of an amylin or an amylin agonist, for example, the amylin agonist analogue ^{25,28,29}Pro-h-amylin. The amylin or amylin agonist may be administered alone or in
15 conjunction with another obesity relief agent. In one aspect, the invention is directed to a method of treating obesity in a human subject comprising administering to said subject an effective amount of an amylin or such an amylin agonist. By "treating" is meant the management and care of a
20 patient for the purpose of combating the disease, condition or disorder, and includes the administration of an amylin or an amylin agonist to prevent the onset of symptoms or complications, alleviating the symptoms or complications, or eliminating the disease condition or disorder. Treating
25 obesity therefor includes the inhibition of weight gain and inducing weight loss in patients in need thereof. Additionally, treating obesity is meant to include controlling weight for cosmetic purposes in humans, that is to control body weight to improve bodily appearance.

The term "amylin" is understood to include compounds such as those defined in U.S. Patent No. 5,234,906, issued August 10, 1993, for "Hyperglycemic Compositions," the contents of which are hereby incorporated by reference. For example, it includes the human peptide hormone referred to as amylin and secreted from the beta cells of the pancreas, and species variations of it. "Amylin agonist" is also a term known in the art, and refers to a compound which mimics effects of amylin. An amylin agonist may be a peptide or a non-peptide compound, and includes amylin agonist analogues.

The term "amylin agonist analogue" is understood to refer to derivatives of an amylin which act as amylin agonists, normally, it is presently believed, by virtue of binding to or otherwise directly or indirectly interacting with an amylin receptor or other receptor or receptors with which amylin itself may interact to elicit a biological response. Useful amylin agonist analogues include those identified in an International Application, WPI Acc. No. 93-182488/22, entitled "New Amylin Agonist Peptides Used for Treatment and Prevention of Hypoglycemia and Diabetes Mellitus," the contents of which are also hereby incorporated by reference.

In a preferred embodiment, the amylin agonist is an amylin agonist analogue, preferably, ^{25,28,29}Pro-h-amylin. ^{25,28,29}Pro-h-amylin and other amylin agonist analogues are described and claimed in U.S. Patent No. 5,686,411, issued November 11, 1997, the contents of which are also hereby incorporated by reference.

In another aspect, the present invention is directed to novel methods of reducing insulin-induced weight

gain in human subjects who are taking insulin by administering a therapeutically effective amount of an amylin or an amylin agonist. In one embodiment, the subject has diabetes mellitus, for example, type 1 or type 2 diabetes mellitus.

5 In a preferred embodiment, the amylin agonist is ^{25,28,29}Pro-h-amylin.

DETAILED DESCRIPTION OF THE INVENTION

10 The study described in Example 1 showed that administration of the amylin agonist ^{25,28,29}Pro-h-amylin (pramlintide) to insulin-using diabetics (type 2) resulted in a decrease in body weight after 4 weeks which achieved statistical significance within two dosage groups, 60 µg TID and 60 µg QID. The study described in Example 2 showed that 15 administration of pramlintide (30 µg or 60 µg QID) to type 1 diabetes resulted in a statistically significant decrease in body weight, compared to placebo, at 13, 26 and 52 weeks. The study described in Example 3 showed that administration 20 of pramlintide (30, 75 or 150 µg TID) to patients with type 2 diabetes who require insulin resulted in a statistically significant decrease in body weight, compared to placebo, at 13, 26 and 52 weeks. These results are in sharp contrast to treatment with insulin alone in patients with type 1 or type 25 2 diabetes, which is usually associated with weight gain.

Amylin agonist analogues useful in this invention include amylin agonist analogues described and claimed in the above-noted U.S. Patent No. 5,686,411. Amylin agonists include agonist analogues of amylin as follows:

1. An agonist analogue of amylin having the amino acid sequence:

¹A₁-X-Asn-Thr-⁵Ala-Thr-Y-Ala-Thr-¹⁰Gln-Arg-Leu-
B₁-Asn-¹⁵Phe-Leu-C₁-D₁-E₁-²⁰F₁-G₁-Asn-H₁-Gly-²⁵Pro-I₁-
Leu-Pro-J₁-³⁰Thr-K₁-Val-Gly-Ser-³⁵Asn-Thr-Tyr-Z

wherein

A₁ is Lys, Ala, Ser or hydrogen;

B₁ is Ala, Ser or Thr;

C₁ is Val, Leu or Ile;

D₁ is His or Arg;

E₁ is Ser or Thr;

F₁ is Ser, Thr, Gln or Asn;

G₁ is Asn, Gln or His;

H₁ is Phe, Leu or Tyr;

I₁ is Ile, Val, Ala or Leu;

J₁ is Ser, Pro or Thr;

K₁ is Asn, Asp or Gln;

X and Y are independently selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage, wherein said intramolecular linkage comprises a disulfide bond, a lactam or a thioether linkage; and Z is amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy; and provided that when A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is Arg, E₁ is Ser, F₁ is Ser, G₁ is Asn, H₁ is Leu, I₁ is Val, J₁ is Pro, and K₁ is Asn; then one or more of A₁ to K₁ is a D-amino acid and Z is selected from the group consisting of alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy.

2. An agonist analogue of amylin having the amino acid sequence:

¹A₁-X-Asn-Thr-⁵Ala-Thr-Y-Ala-Thr-¹⁰Gln-Arg-Leu-
B₁-Asn-¹⁵Phe-Leu-C₁-D₁-E₁-²⁰F₁-G₁-Asn-H₁-Gly-²⁵Pro-I₁-
Leu-J₁-Pro-³⁰Thr-K₁-Val-Gly-Ser-³⁵Asn-Thr-Tyr-Z

wherein

A₁ is Lys, Ala, Ser or hydrogen;

B₁ is Ala, Ser or Thr;

C₁ is Val, Leu or Ile;

D₁ is His or Arg;

E₁ is Ser or Thr;

F₁ is Ser, Thr, Gln or Asn;

G₁ is Asn, Gln or His;

H₁ is Phe, Leu or Tyr;

I₁ is Ile, Val, Ala or Leu;

J₁ is Ser, Pro, Leu, Ile or Thr;

K₁ is Asn, Asp or Gln;

X and Y are independently selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage, wherein said intramolecular linkage comprises a disulfide bond, a lactam or a thioether linkage; and Z is amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy; and provided that when

(a) A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is Arg, E₁ is Ser, F₁ is Ser, G₁ is Asn, H₁ is Leu, I₁ is Val, J₁ is Pro and K₁ is Asn; or

(b) A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is His, E₁ is Ser, F₁ is Asn, G₁ is Asn, H₁ is Leu, I₁ is Val, J₁ is Ser and K₁ is Asn;

then one or more of A₁ to K₁ is a D-amino acid and Z is selected from the group consisting of alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy.

5 3. An agonist analogue of amylin having the amino acid sequence:

¹A₁-X-Asn-Thr-⁵Ala-Thr-Y-Ala-Thr-¹⁰Gln-Arg-Leu-
B₁-Asn-¹⁵Phe-Leu-C₁-D₁-E₁-²⁰F₁-G₁-Asn-H₁-Gly-²⁵I₁-J₁-
Leu-Pro-Pro-³⁰Thr-K₁-Val-Gly-Ser-³⁵Asn-Thr-Tyr-Z

10 wherein

A₁ is Lys, Ala, Ser or hydrogen;

B₁ is Ala, Ser or Thr;

C₁ is Val, Leu or Ile;

D₁ is His or Arg;

15 E₁ is Ser or Thr;

F₁ is Ser, Thr, Gln or Asn;

G₁ is Asn, Gln or His;

H₁ is Phe, Leu or Tyr;

I₁ is Ala or Pro;

20 J₁ is Ile, Val, Ala or Leu;

K₁ is Asn, Asp or Gln; X and Y are independently

selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage, wherein said intramolecular linkage comprises a disulfide

25 bond, a lactam or a thioether linkage; and Z is amino,

alkylamino, dialkylamino, cycloalkylamino, arylamino,

aralkylamino, alkyloxy, aryloxy or aralkyloxy; and provided

that when A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is Arg, E₁ is

Ser, F₁ is Ser, G₁ is Asn, H₁ is Leu, I₁ is Pro, J₁ is Val and

30 K₁ is Asn; then one or more of A₁ to K₁ is a D-amino acid and

Z is selected from the group consisting of alkylamino, dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy.

4. An agonist analogue of amylin having the amino acid sequence:

¹A₁-X-Asn-Thr-⁵Ala-Thr-Y-Ala-Thr-¹⁰Gln-Arg-Leu-
B₁-Asn-¹⁵Phe-Leu-C₁-D₁-E₁-²⁰F₁-G₁-Asn-H₁-Gly-²⁵Pro-I₁-
Leu-Pro-Pro-³⁰Thr-J₁-Val-Gly-Ser-³⁵Asn-Thr-Tyr-Z

wherein

10 A₁ is Lys, Ala, Ser or hydrogen;

B₁ is Ala, Ser or Thr;

C₁ is Val, Leu or Ile;

D₁ is His or Arg;

E₁ is Ser or Thr;

15 F₁ is Ser, Thr, Gln or Asn;

G₁ is Asn, Gln or His;

H₁ is Phe, Leu or Tyr;

I₁ is Ile, Val, Ala or Leu;

J₁ is Asn, Asp or Gln; X and Y are independently

20 selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage wherein said intramolecular linkage comprises a disulfide bond, a lactam or a thioether linkage; and Z is amino, alkylamino, dialkylamino, cycloalkylamino, arylamino,

25 aralkylamino, alkyloxy, aryloxy or aralkyloxy; and provided that when A₁ is Lys, B₁ is Ala, C₁ is Val, D₁ is Arg, E₁ is Ser, F₁ is Ser, G₁ is Asn, H₁ is Leu, I₁ is Val and J₁ is Asn; then one or more of A₁ to K₁ is a D-amino acid and Z is selected from the group consisting of alkylamino,

dialkylamino, cycloalkylamino, arylamino, aralkylamino, alkyloxy, aryloxy or aralkyloxy.

Preferred amylin agonist analogues include ^{25,28,29}Pro-h-amylin, ¹⁸Arg^{25,28,29}Pro-h-amylin and ¹⁸Arg^{25,28}Pro-h-amylin.

Activity as amylin agonists can be confirmed and quantified by performing various screening assays, including the nucleus accumbens receptor binding assay described below in Example 7, followed by the soleus muscle assay described below in Example 8, a gastric emptying assay described below in Example 9 or 10, or by the ability to induce hypocalcemia or reduce postprandial hyperglycemia in mammals, as described herein.

The receptor binding assay, a competition assay which measures the ability of compounds to bind specifically to membrane-bound amylin receptors, is described and claimed in United States Patent No. 5,264,372, issued November 23, 1993, the disclosure of which is incorporated herein by reference. The receptor binding assay is also described in Example 7 below. A preferred source of the membrane preparations used in the assay is the basal forebrain which comprises membranes from the nucleus accumbens and surrounding regions. Compounds being assayed compete for binding to these receptor preparations with ¹²⁵I Bolton Hunter rat amylin. Competition curves, wherein the amount bound (B) is plotted as a function of the log of the concentration of ligand are analyzed by computer, using analyses by nonlinear regression to a 4-parameter logistic equation (Inplot program; GraphPAD Software, San Diego, California) or the ALLFIT program of DeLean et al. (ALLFIT, Version 2.7 (NIH,

Bethesda, MD 20892)). Munson and Rodbard, Anal. Biochem. 107:220-239 (1980).

Assays of biological activity of amylin agonists in the soleus muscle may be performed using previously described methods (Leighton, B. and Cooper, *Nature*, 335:632-635 (1988); Cooper, et al., *Proc. Natl. Acad. Sci. USA* 85:7763-7766 (1988)), in which amylin agonist activity may be assessed by measuring the inhibition of insulin-stimulated glycogen synthesis. The soleus muscle assay is also described in Example 8 below.

Methods of measuring the rate of gastric emptying are disclosed in, for example, Young et al., *Diabetologia*, 38(6):642-648 (1995). In a phenol red method, which is described in Example 9 below, conscious rats receive by gavage an acoloric gel containing methyl cellulose and a phenol red indicator. Twenty minutes after gavage, animals are anesthetized using halothane, the stomach exposed and clamped at the pyloric and lower esophageal sphincters, removed and opened into an alkaline solution. Stomach content may be derived from the intensity of the phenol red in the alkaline solution, measured by absorbance at a wavelength of 560 nm. In a tritiated glucose method, which is described in Example 10 below, conscious rats are gavaged with tritiated glucose in water. The rats are gently restrained by the tail, the tip of which is anesthetized using lidocaine. Tritium in the plasma separated from tail blood is collected at various timepoints and detected in a beta counter. Test compounds are normally administered about one minute before gavage.

Effects of amylin or amylin agonists on body weight can be identified, evaluated, or screened for using the methods described in Examples 1-3 below, or other art-known or equivalent methods for determining effect on body weight. Preferred amylin agonist compounds exhibit activity in the receptor binding assay on the order of less than about 1 to 5 nM, preferably less than about 1 nM and more preferably less than about 50 pM. In the soleus muscle assay, preferred amylin agonist compounds show EC_{50} values on the order of less than about 1 to 10 micromolar. In the gastric emptying assays, preferred agonist compounds show ED_{50} values on the order of less than 100 μ g/rat.

Amylin and peptide amylin agonists may be prepared using standard solid-phase peptide synthesis techniques and preferably an automated or semiautomated peptide synthesizer. Typically, using such techniques, an α -N-carbamoyl protected amino acid and an amino acid attached to the growing peptide chain on a resin are coupled at room temperature in an inert solvent such as dimethylformamide, N-methylpyrrolidinone or methylene chloride in the presence of coupling agents such as dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in the presence of a base such as diisopropylethylamine. The α -2N-carbamoyl protecting group is removed from the resulting peptide-resin using a reagent such as trifluoroacetic acid or piperidine, and the coupling reaction repeated with the next desired N-protected amino acid to be added to the peptide chain. Suitable N-protecting groups are well known in the art, with t-butyloxycarbonyl (tBoc) and fluorenylmethoxycarbonyl (Fmoc) being preferred herein.

The solvents, amino acid derivatives and

4-methylbenzhydryl-amine resin used in the peptide synthesizer may be purchased from Applied Biosystems Inc. (Foster City, CA). The following side-chain protected amino acids may be purchased from Applied Biosystems, Inc.: Boc-Arg(Mts), Fmoc-Arg(Pmc), Boc-Thr(Bzl), Fmoc-Thr(t-Bu), Boc-Ser(Bzl), Fmoc-Ser(t-Bu), Boc-Tyr(BrZ), Fmoc-Tyr(t-Bu), Boc-Lys(Cl-Z), Fmoc-Lys(Boc), Boc-Glu(Bzl), Fmoc-Glu(t-Bu), Fmoc-His(Trt), Fmoc-Asn(Trt), and Fmoc-Gln(Trt). Boc-His(BOM) may be purchased from Applied Biosystems, Inc. or Bachem Inc. (Torrance, CA). Anisole, methylsulfide, phenol, ethanedithiol, and thioanisole may be obtained from Aldrich Chemical Company (Milwaukee, WI). Air Products and Chemicals (Allentown, PA) supplies HF. Ethyl ether, acetic acid and methanol may be purchased from Fisher Scientific (Pittsburgh, PA).

Solid phase peptide synthesis may be carried out with an automatic peptide synthesizer (Model 430A, Applied Biosystems Inc., Foster City, CA) using the NMP/HOBt (Option 1) system and TboC or Fmoc chemistry (see, Applied Biosystems User's Manual for the ABI 430A Peptide Synthesizer, Version 1.3B July 1, 1988, section 6, pp. 49-70, Applied Biosystems, Inc., Foster City, CA) with capping. Boc-peptide-resins may be cleaved with HF (-5°C to 0°C, 1 hour). The peptide may be extracted from the resin with alternating water and acetic acid, and the filtrates lyophilized. The Fmoc-peptide resins may be cleaved according to standard methods (Introduction to Cleavage Techniques, Applied Biosystems, Inc., 1990, pp. 6-12). Peptides may be also be assembled using an Advanced Chem Tech Synthesizer (Model MPS 350, Louisville, Kentucky).

Peptides may be purified by RP-HPLC (preparative and analytical) using a Waters Delta Prep 3000 system. A C4, C8 or C18 preparative column (10 μ , 2.2 x 25 cm; Vydac, Hesperia, CA) may be used to isolate peptides, and purity may be determined using a C4, C8 or C18 analytical column (5 μ , 0.46 x 25 cm; Vydac). Solvents (A=0.1% TFA/water and B=0.1% TFA/CH₃CN) may be delivered to the analytical column at a flowrate of 1.0 ml/min and to the preparative column at 15 ml/min. Amino acid analyses may be performed on the Waters Pico Tag system and processed using the Maxima program. Peptides may be hydrolyzed by vapor-phase acid hydrolysis (115°C, 20-24 h). Hydrolysates may be derivatized and analyzed by standard methods (Cohen, et al., The Pico Tag Method: A Manual of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation, Milford, MA (1989)). Fast atom bombardment analysis may be carried out by M-Scan, Incorporated (West Chester, PA). Mass calibration may be performed using cesium iodide or cesium iodide/glycerol. Plasma desorption ionization analysis using time of flight detection may be carried out on an Applied Biosystems Bio-Ion 20 mass spectrometer.

Peptide compounds useful in the invention may also be prepared using recombinant DNA techniques, using methods now known in the art. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor (1989). Non-peptide compounds useful in the present invention may be prepared by art-known methods.

The compounds referenced above may form salts with various inorganic and organic acids and bases. Such salts include salts prepared with organic and inorganic acids, for

example, HCl, HBr, H₂SO₄, H₃PO₄, trifluoroacetic acid, acetic acid, formic acid, methanesulfonic acid, toluenesulfonic acid, maleic acid, fumaric acid and camphorsulfonic acid. Salts prepared with bases include ammonium salts, alkali metal salts, e.g., sodium and potassium salts, and alkali earth salts, e.g., calcium and magnesium salts. Acetate, hydrochloride, and trifluoroacetate salts are preferred. Acetate salts are most preferred. The salts may be formed by conventional means, as by reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is then removed in vacuo or by freeze-drying or by exchanging the ions of an existing salt for another ion on a suitable ion exchange resin.

Compositions useful in the invention may conveniently be provided in the form of formulations suitable for parenteral (including intravenous, intramuscular and subcutaneous) or nasal or oral administration. A suitable administration format may best be determined by a medical practitioner for each patient individually. Suitable pharmaceutically acceptable carriers and their formulation are described in standard formulation treatises, e.g., Remington's Pharmaceutical Sciences by E.W. Martin. See also Wang, Y.J. and Hanson, M.A. "Parenteral Formulations of Proteins and Peptides: Stability and Stabilizers," Journal of Parenteral Science and Technology, Technical Report No. 10, Supp. 42:2S (1988). Compounds provided as parenteral compositions for injection or infusion can, for example, be suspended in an inert oil, suitably a vegetable

oil such as sesame, peanut, olive oil, or other acceptable carrier. Preferably, they are suspended in an aqueous carrier, for example, in an isotonic buffer solution at a pH of about 5.6 to 7.4. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH buffering agents. Useful buffers include for example, sodium acetate/acetic acid buffers. A form of repository or "depot" slow release preparation may be used so that therapeutically effective amounts of the preparation are delivered into the bloodstream over many hours or days following transdermal injection or delivery.

Preferably, these parenteral dosage forms are prepared according to the commonly owned patent application entitled, "Parenteral, Liquid Formulations for Amylin Agonist Peptides," Serial No. 60/035,140, filed January 8, 1997, and United States Application Serial No. 09/005,262, filed January 8, 1998, which are incorporated herein by this reference, and include approximately 0.01 to 0.5 % (w/v), respectively, of an amylin or an amylin agonist in a aqueous system along with approximately 0.02 to 0.5 % (w/v) of an acetate, phosphate, citrate or glutamate buffer to obtain a pH of the final composition of approximately 3.0 to 6.0 (more preferably 3.0 to 5.5), as well as approximately 1.0 to 10 % (w/v) of a carbohydrate or polyhydric alcohol toncifier in an aqueous continuous phase. Approximately 0.005 to 1.0 % (w/v) of an antimicrobial preservative selected from the group consisting of m-cresol, benzyl alcohol, methyl, ethyl,

propyl and butyl parabens and phenol is also present in the preferred formulation of product designed to allow the patient to withdraw multiple doses. A stabilizer is not required. A sufficient amount of water for injection is used to obtain the desired concentration of solution. Sodium chloride, as well as other excipients, may also be present, if desired. Such excipients, however, must maintain the overall stability of the amylin or amylin agonist peptide. Liquid formulations should be substantially isotonic, that is, within $\pm 20\%$ of isotonicity, and preferably within 10% of isotonicity. Most preferably, in the amylin or amylin agonist formulation for parenteral administration, the polyhydric alcohol is mannitol, the buffer is an acetate buffer, the preservative is approximately 0.1 to 0.3% (w/v) of m-cresol, and the pH is approximately 3.7 to 4.3 . The desired isotonicity may be accomplished using sodium chloride or other pharmaceutically acceptable salts.

If desired, solutions of the above compositions may be thickened with a thickening agent such as methyl cellulose. They may be prepared in emulsified form, either water in oil or oil in water. Any of a wide variety of pharmaceutically acceptable emulsifying agents may be employed including, for example, acacia powder, a non-ionic surfactant (such as a Tween), or an ionic surfactant (such as alkali polyether alcohol sulfates or sulfonates, e.g., a Triton).

Compositions useful in the invention are prepared by mixing the ingredients following generally accepted procedures. For example, the selected components may be simply mixed in a blender or other standard device to produce

a concentrated mixture which may then be adjusted to the final concentration and viscosity by the addition of water or thickening agent and possibly a buffer to control pH or an additional solute to control tonicity.

5 For use by the physician, the compositions will be provided in dosage unit form containing an amount of an amylin or amylin agonist, for example, an amylin agonist analogue compound which will be effective in one or multiple doses to control obesity at the selected level.

10 Therapeutically effective amounts of an amylin or amylin agonist, such as an amylin agonist analogue, for use in the control of obesity are those that decrease body weight. As will be recognized by those in the field, an effective amount of therapeutic agent will vary with many factors including
15 the age and weight of the patient, the patient's physical condition, the action to be obtained and other factors.

The effective single, divided or continuous analgesic doses of the compounds, for example, including ^{25,28,29}Pro-h-amylin, ¹⁸Arg^{25,28,29}Pro-h-amylin and ¹⁸Arg^{25,28}Pro-h-amylin will typically be in the range of about 0.01 to about
20 5 mg/day, preferably about 0.05 to about 2 mg/day and more preferably about 0.1 to 1 mg/day, for a 70 kg patient, administered in a single, divided or continuous doses. The exact dose to be administered is determined by the attending
25 clinician and is dependent upon a number of factors, including, these noted above. Administration should begin at the first sign of obesity. Administration may be by injection or infusion, preferably intravenous, subcutaneous or intramuscular. Orally active compounds may be taken
30 orally, however dosages should be increased 5-10 fold.

Generally, in treating or preventing obesity, the compounds of this invention may be administered to patients in need of such treatment in a dosage ranges similar to those given above, however, the compounds may be administered more frequently, for example, one, two, or three times a day or continuously. Preferably, the doses of peptide agonists, for example, pramlintide, are administered subcutaneously in 30-300 μ g doses given from one to four times a day, and more preferably from 30-120 μ g doses given two to four times per day.

To assist in understanding the present invention, the following Example is included which describes the results of a set of experiments. The studies relating to this invention should not, of course, be construed as specifically limiting the invention and such variations of the invention, now known or later developed, which would be within the purview of one skilled in the art are considered to fall within the scope of the invention as described herein and hereinafter claimed.

EXAMPLE 1

Measurement of Body Weight: 4-Week Study in Type 2 Diabetics Who Require Insulin

Study participants were males and females 25 to 78 years of age with a history of Type II diabetes mellitus requiring treatment with insulin for at least 6 months prior to the pre-screening visit. Patients had a body weight not varying more than 45% from the desirable weight before

admission into the study (based upon Metropolitan Life Tables). The study employed methods described in Thompson et al., Diabetes 46:632-636 (1997). Following a placebo lead-in period, patients were randomized to receive placebo or one of three dose regimens of ^{25,28,29}Pro-h-amylin (pramlintide) for 4 weeks: 30 µg QID (before breakfast, lunch, dinner and evening snack), 60 µg TID (before breakfast, lunch and dinner) or 60 µg QID (before breakfast, lunch, dinner and evening snack). Throughout the study drug period, patients self-administered four injections of study drug daily, within 15 minutes of each meal and the evening snack. During the double-blind period, patients randomized to pramlintide 60 µg TID administered placebo before the evening snack. Both pramlintide and placebo were administered as separate injections into the subcutaneous tissue of the anterior abdominal wall; the specific site was alternated after each injection. Patients were instructed to remain on their usual diet, insulin and exercise regimens throughout the study, unless otherwise instructed by the investigator, and to abstain from alcoholic beverages prior to all clinic visits.

As shown in Table I, there was a statistically significant weight reduction weight from baseline to Week 4 within the pramlintide 60 µg TID (mean = - 0.89 kg, p = 0.0056) and pramlintide 60 µg QID (mean = - 0.72 kg, p = 0.0014) groups. With the Hochberg adjustment for multiple comparisons, there was no statistically significant change in body weight from baseline to Week 4 in any of the three pramlintide groups compared to the placebo group. Thus, pramlintide administration with continued insulin use improved glycemic control with a decrease in body weight

which achieved statistical significance within the 60 μ g TID and QID groups. This decrease is in sharp contrast to weight gain usually associated with improved glucose control achieved with insulin alone in patients with Type 2 diabetes.

Table I. Body Weight: Change from Baseline to Week 4

Treatment Group	N	Baseline	Change at Week 4		p-Value*	
		Mean (kg)	Mean (kg)	Median (kg)	Within Study Drug Group	Placebo Comparison
Placebo	47	87.0	-0.04	0.0	NS	NAP
Pramlintide 30 μ g QID	47	88.5	-0.36	-0.45	NS	NS
Pramlintide 60 μ g TID	48	86.2	-0.89	-1.05	0.0056	NS
Pramlintide 60 μ g QID	51	81.5	-0.72	-0.45	0.0014	NS

* Student's t-test (within study-drug group comparison). Two-way ANOVA (placebo comparison) with the Hochberg Adjustment.
NS = Not statistically significant; NAP = Not applicable.

EXAMPLE 2

Measurement of Body Weight: 52-Week Study in Type 1 Diabetics

This study was a multicenter, double-blind, placebo-controlled, parallel group study with a potential dose escalation. Study participants were males and females between the ages of 16 and 70 years with Type 1 diabetes mellitus. Four subcutaneous injections of 30 μ g pramlintide or placebo were self-administered daily, one before each meal and a bedtime snack. Certain patients (those in the pramlintide arm who had a reduction of HbA1c from baseline of less than 1.0% after 13 weeks of treatment) were re-

randomized at 20 weeks to either 30 μ g or 60 μ g QID for the remainder of the study. Patients in this study were treated with study medication formulated at pH 4.0 at a concentration allowing injection of 0.1 mL per dose. 477 patients received at least one dose of study medication (pramlintide or placebo). Of the 477 patients randomized and dosed, 341 completed the 52-week study.

Patients treated with pramlintide experienced a clinically meaningful and statistically significant decrease in body weight, compared to placebo, at 13, 26 and 52 weeks (Table II). The greatest difference from placebo was observed at 26 weeks and 52 weeks (decrease of at least 1.2 kg compared with placebo at each time point). Weight loss occurred particularly in those patients having a baseline body mass index (BMI) of at least 27.0 kg/m², indicating greatest benefit among obese patients (Table III).

Pramlintide-taking patients within the subgroup of patients with baseline HbA1c levels of at least 8.0% and stable insulin experienced a mean decrease in body weight compared to placebo at all three time points (Table IV). This observation is consistent with the well-known effect of insulin to facilitate body weight gain. Thus, pramlintide appears to reduce insulin-induced weight gain.

Normally distributed data were analyzed using two-way analysis of variance. In cases where data were found not to follow a normal distribution, non-parametric methods (Kruskal-Wallis test) based on ranks were employed. In these cases, the Hodges-Lehman estimator for the difference from placebo is presented instead of the mean.

Hodges-Lehman Estimator for Difference from Placebo	-	-1.3
p-value †	-	0.0001*
Week 52 (12 Months)		
Mean (SE)	77.1 (1.1)	76.0 (1.1)
Median	75.7	76.4
Range	44.8, 126.8	48.2, 109.9
Change from Baseline		
Mean (SE)	0.8 (0.3)	-0.5 (0.3)
Median	0.8	-0.5
Range	-11.5, 11.2	-12.0, 13.7
Mean Difference from Placebo	-	-1.3
p-value ‡	-	0.0137*

† Kruskal-Wallis test.

‡ Two-way ANOVA.

* Statistically significant difference compared to placebo.

Table III

Body Weight: Changes from Baseline for Patients With Baseline BMI ≥ 27.0 kg/m²
Weights at Weeks 13, 26, and 52

BMI Subgroup/Body Weight (kg)	Placebo (N=154)	Pramlintide 30 or 60 μ g QID (N=163)
Baseline BMI ≥ 27.0 kg/m ²		
Change at Week 52		
N	51	53
Mean (SE)	0.4 (0.53)	-1.8 (0.65)
Range	-6.4, 11.2	-12.0, 9.1
Baseline BMI < 27.0 kg/m ²		
Change at Week 52		
N	103	110
Mean (SE)	1.0 (0.36)	0.1 (0.28)
Range	-11.5, 11.2	-5.0, 13.7

Table of IV

Body Weight: Changes from Baseline
 patients with HbA_{1c} ≥8.0%, Insulin Within ±10% of Baseline Weights at Weeks 13, 26, and 52

Time Point/Body Weight (kg)	Placebo (N=31)	Pramlintide 30 or 60 µg QID (N=39)
Baseline		
Mean (SE)	75.9 (2.2)	81.3 (2.2)
Median	74.6	79.4
Range	52.4, 113.6	55.5, 113.6
Week 13 (3 Months)		
Mean (SE)	75.8 (2.1)	80.3 (2.1)
Median	74.1	78.6
Range	56.5, 108.2	56.4, 110.5
Change from Baseline		
Mean (SE)	-0.1 (0.4)	-1.0 (0.4)
Median	0	-1.4
Range	-6.4, 4.1	-7.6, 8.2
Mean Difference from Placebo	-	-0.9
p-value †	-	0.0745
Week 26 (6 months)		
Mean (SE)	76.2 (2.0)	80.8 (2.1)
Median	75.9	80.5
Range	54.9, 108.2	55.5, 111.2
Change from Baseline		
Mean (SE)	0.3 (0.5)	-0.5 (0.6)
Median	0.4	0
Range	-5.4, 5.9	-10.5, 9.1

Mean Difference from Placebo	-	-0.8
p-value †	-	0.1197
Week 52 (12 Months)		
Mean (SE)	76.5 (2.1)	81.7 (2.1)
Median	75.9	79.6
Range	54.5, 109.1	56.4, 109.9
Change from Baseline		
Mean (SE)	0.6 (0.7)	0.4 (0.6)
Median	0.7	0.2
Range	-7.0, 11.2	-10.0, 13.7
Mean Difference from Placebo	-	-0.2
p-value †	-	0.2441

† Two-way ANOVA

* Statistically significant difference compared to placebo

EXAMPLE 3

Measurement of Body Weight: 52-Week Study in Type 2 Diabetics Who Require Insulin

Table II

Body Weight: Changes from Baseline
Weights at Weeks 13, 26, and 52

Time Point/Body Weight (kg)	Placebo (N=154)	Pramlintide 30 or 60 µg QID (N=163)
Baseline		
Mean (SE)	76.3 (1.1)	76.4 (1.1)
Median	75.0	75.9
Range	47, 121.8	46.4, 113.6
Week 13 (3 Months)		
Mean (SE)	76.5 (1.1)	75.4 (1.1)
Median	75.1	75.6
Range	45, 125.7	47.3, 110.5
Change from Baseline		
Mean (SE)	0.2 (0.2)	-1.0 (0.2)
Median	0	-1.0
Range	-6.0, 8.2	-7.6, 8.2
Hodges-Lehman Estimator for Difference from Placebo	-	-1.2
p-value †	-	0.0001*
Week 26 (6 months)		
Mean (SE)	76.9 (1.1)	75.5 (1.1)
Median	75.9	76.4
Range	45.8, 126.8	46.4, 111.2
Change from Baseline		
Mean (SE)	0.6 (0.2)	-0.9 (0.3)
Median	0.55	-0.5
Range	-7.3, 9.3	-23.5, 9.1
Hodges-Lehman Estimator for Difference from Placebo	-	-1.3
p-value †	-	0.0001*
Week 52 (12 Months)		
Mean (SE)	77.1 (1.1)	76.0 (1.1)
Median	75.7	76.4
Range	44.8, 126.8	48.2, 109.9
Change from Baseline		
Mean (SE)	0.8 (0.3)	-0.5 (0.3)
Median	0.8	-0.5
Range	-11.5, 11.2	-12.8, 13.7
Mean Difference from Placebo	-	-1.3
p-value ‡	-	0.0137*

† Kruskal-Wallis test

‡ Two-way ANOVA

* Statistically significant difference compared to placebo

Table III

Body Weight: Changes from Baseline for Patients With Baseline BMI ≥ 27.0 kg/m² or <27.0 kg/m²
Weights at Weeks 13, 26, and 52

	Placebo (N=164)	Pramlintide 30 or 60 μ g QID (N=164)
10 BMI Subgroup/Body Weight (kg)		
15 Baseline BMI ≥ 27.0 kg/m ²		
Change at Week 52		
N	51	53
Mean (SE)	0.4 (0.53)	-1.8 (0.65)
Range	-6.4, 11.2	-12.0, 9.1
20 Baseline BMI <27.0 kg/m ²		
Change at Week 52		
N	103	110
Mean (SE)	1.0 (0.38)	0.1 (0.28)
Range	-11.5, 11.2	-5.0, 13.7
25		
30		

Table IV

Body Weight: Changes from Baseline
 Patients with HbA_{1c} $\geq 8.0\%$, Insulin Within $\pm 10\%$ of Baseline Weights at Weeks 13, 26, and 52

Time Point/Body Weight (kg)	Placebo (N=31)	Pramlintide 30 or 60 μg QID (N=39)
Baseline		
Mean (SE)	75.9 (2.2)	81.3 (2.2)
Median	74.6	79.4
Range	52.4, 113.6	55.5, 113.6
Week 13 (3 Months)		
Mean (SE)	75.8 (2.1)	80.3 (2.1)
Median	74.1	78.6
Range	56.5, 108.2	56.4, 110.5
Change from Baseline		
Mean (SE)	-0.1 (0.4)	-1.0 (0.4)
Median	0	-1.4
Range	-6.4, 4.1	-7.6, 8.2
Mean Difference from Placebo	-	-0.9
p-value †	-	0.0745
Week 26 (6 months)		
Mean (SE)	76.2 (2.0)	80.8 (2.1)
Median	75.9	80.5
Range	54.9, 108.2	55.5, 111.2
Change from Baseline		
Mean (SE)	0.3 (0.5)	-0.5 (0.6)
Median	0.4	0
Range	-5.4, 5.9	-10.5, 9.1
Mean Difference from Placebo	-	-0.8
p-value †	-	0.1197
Week 52 (12 Months)		
Mean (SE)	76.5 (2.1)	81.7 (2.1)
Median	75.9	78.6
Range	54.5, 109.1	56.4, 109.9
Change from Baseline		
Mean (SE)	0.6 (0.7)	0.4 (0.6)
Median	0.7	0.2
Range	-7.0, 11.2	-10.0, 13.7
Mean Difference from Placebo	-	-0.2
p-value †	-	0.2441

† Two-way ANOVA.

* Statistically significant difference compared to placebo

EXAMPLE 3

Measurement of Body Weight: 52-Week Study in Type 2
Diabetics Who Require Insulin

This study was a multicenter, double-blind, placebo-controlled, parallel group, dose ranging study. Study participants were males and females between the ages of 18 and 75 years with Type 2 diabetes mellitus who require insulin. Three subcutaneous injections of pramlintide (30, 75 or 150 μg TID) or placebo (TID) were self-administered daily, one before each meal, for 52 weeks. Patients in this study were treated with study medication formulated at pH 4.7 at a concentration requiring injection of 0.3 mL per dose. The double-blind treatment period was preceded by a 3- to 10-day single-blind, placebo lead-in period. Of the 539 patients randomized and dosed, 381 completed the 52-week study.

Patients treated with any of the three doses of pramlintide experienced a clinically meaningful and statistically significant decrease in body weight, compared to placebo, at 13, 26 and 52 weeks (Table V). The greatest difference from placebo was observed at 26 weeks and 52 weeks (decreases of 2.3 and 2.7 kg compared with placebo at these time points). Weight of placebo treated patients increased relative to baseline at all three time points, in contrast with weight decreases in the three pramlintide groups at all time points. Weight loss occurred both in those patients having a baseline body mass index (BMI) of at least 27.0 kg/m^2 and in those having a baseline BMI of less than 27.0 kg/m^2 (Table VI).

Pramlintide patients in all three groups with baseline HbA1c levels of at least 8.0% and on stable insulin experienced a decrease in body weight compared to placebo at

all time points (Table VII). The magnitude of the response was in general comparable to that observed for all patients, suggesting an effect independent of changes in insulin dose.

Normally distributed data were analyzed using two-way analysis of variance (with the Hochberg adjustment to the Bonferroni procedure for multiple comparisons). In cases where data were found not to follow a normal distribution, non-parametric methods (Kruskal-Wallis test) based on ranks were employed. In these cases, the Hodges-Lehman estimator for the difference from placebo is presented instead of the mean.

Table V

Body Weight: Changes from Baseline
Weights at Weeks 13, 26, and 52

Time Point/Body Weight (kg)	Placebo (N=89)	Pramlintide 30 µg TID (N=86)	Pramlintide 75 µg TID (N=93)	Pramlintide 150 µg TID (N=77)
Baseline				
Mean (SE)	90.6 (1.6)	90.3 (1.8)	93.2 (1.8)	94.3 (2.1)
Median	90.3	89.15	92.3	95.7
Range	59.5, 130.9	60.0, 140.0	51.8, 165.0	57.3, 158.1
Week 13 (3 Months)				
Mean (SE)	91.3 (1.6)	89.8 (1.8)	92.5 (1.9)	92.7 (2.1)
Median	90.0	89.3	92.3	92.3
Range	60.5, 132.9	57.7, 142.7	49.1, 166.8	56.4, 156.8
Change from Baseline				
Mean (SE)	0.6 (0.2)	-0.5 (0.3)	-0.6 (0.4)	-1.6 (0.3)
Median	0.5	-0.7	-0.4	-1.4
Range	-6.9, 8.7	-7.7, 10.5	-23.4, 9.5	-9.5, 2.7
Hodges-Lehman Estimator for				
Difference from Placebo	-	-1.1	-0.9	-2.0
p-value †	-	0.0006*	0.0066*	0.0001*
Week 26 (6 months)				
Mean (SE)	91.5 (1.7)	89.7 (1.8)	92.3 (1.8)	92.6 (2.1)
Median	90.5	89.1	92.3	92.3
Range	58.6, 133.0	55.9, 140.9	46.4, 162.5	58.2, 156.4
Change from Baseline				
Mean (SE)	0.8 (0.3)	-0.6 (0.3)	-0.9 (0.5)	-1.7 (0.3)

Median	0.9	-0.45	0.0	-1.5
Range	-5.3, 8.3	-10.7, 11.4	-24.7, 9.0	-10.0, 3.2
Hodges-Lehman Estimator for				
Difference from Placebo	-	-1.3	-1.3	-2.3
p-value †	-	0.0005*	0.0029*	0.0001
Week 52 (12 Months)				
Mean (SE)	91.9 (1.7)	89.6 (1.9)	92.3 (1.9)	92.4 (2.1)
Median	90.0	89.05	92.7	92.7
Range	60.5, 136.6	55.9, 147.3	46.6, 170.8	56.4, 158.2
Change from Baseline				
Mean (SE)	1.2 (0.4)	-0.6 (0.4)	-0.9 (0.5)	-1.9 (0.7)
Median	0.9	-0.4	-0.3	-1.8
Range	-8.0, 20.5	-13.6, 11.9	-31.1, 10.0	-43.2, 7.3
Hodges-Lehman Estimator for				
Difference from Placebo	-	-1.6	-1.4	-2.7
p-value †	-	0.0009*	0.0106*	0.0001

† Kruskal-Wallis test with Hochberg adjustment for multiple comparisons versus placebo

* Statistically significant difference compared to placebo

Table VI

Body Weight: Changes from Baseline for Patients With Baseline BMI ≥ 27.0 kg/m² or < 27.0 kg/m²
Weights at Weeks 13, 26, and 52

BMI Subgroup(Body Weight (kg))	Placebo (N=91)	Pramlintide 30 µg TID (N=88)	Pramlintide 75 µg TID (N=97)	Pramlintide 150 µg TID (N=80)
Baseline BMI ≥ 27.0 kg/m ²				
Change at Week 52				
N	67	67	80	62
Mean (SE)	0.7 (0.43)	-0.3 (0.52)	-0.7 (0.47)	-1.8 (0.80)
Range	-8.0, 10.0	-13.6, 11.9	-13.7, 10.0	-43.2, 7.3
Baseline BMI < 27.0 kg/m ²				
Change at Week 52				
N	24	21	17	18
Mean (SE)	2.4 (1.08)	-0.7 (0.56)	-1.7 (2.07)	-1.9 (0.71)
Range	-3.4, 20.5	-4.7, 6.4	-31.1, 9.0	-7.2, 6.5

Table VII

Body Weight: Changes from Baseline
 Patients with HbA_{1c} ≥8.0%, Insulin Within ± 10% of Baseline Weights at Weeks 13, 26, and 52

Time Point/Body Weight (kg)	Placebo (N=26)	Pramlintide 30 µg TID (N=20)	Pramlintide 75 µg TID (N=22)	Pramlintide 150 µg TID (N=18)
Baseline				
Mean (SE)	84.3 (2.9)	92.7 (3.5)	93.3 (3.2)	99.8 (5.6)
Median	82.15	89.75	90.9	98.9
Range	61.4, 115.7	65.0, 119.5	65.0, 121.8	59.5, 158.1
Week 13 (3 Months)				
Mean (SE)	84.3 (2.8)	92.5 (3.6)	93.3 (3.3)	98.3 (5.7)
Median	81.5	88.85	91.6	97.4
Range	60.5, 112.3	65.9, 123.4	67.3, 121.8	57.7, 156.8
Change from Baseline				
Mean (SE)	0.0 (0.2)	-0.2 (0.5)	-0.0 (0.7)	-1.5 (0.4)
Median	0.45	-0.55	0	-1.55
Range	-3.4, 1.9	-4.6, 6.4	-5.9, 6.4	-3.9, 2.7
Hodges-Lehman Estimator for				
Difference from Placebo	-	-0.5	-0.4	-1.9
p-value †	-	0.2812	0.5827	0.0005*
Week 26 (6 months)				
Mean (SE)	84.8 (2.9)	92.4 (3.6)	93.1 (3.3)	98.1 (5.6)
Median	83.15	89.75	91.8	97.5
Range	60.9, 117.5	64.1, 123.6	71.8, 121.1	58.9, 156.4
Change from Baseline				
Mean (SE)	0.5 (0.3)	-0.3 (0.5)	-0.1 (0.8)	-1.8 (0.5)
Median	0.7	-0.45	0	-1.4

Range	-2.7, 4.7	-3.7, 4.1	-6.8, 7.3	-5.4, 2.0
Hodges-Lehman Estimator for				
Difference from Placebo	-	-0.8	-0.6	-2.2
p-value †	-	0.8903	0.3616	0.0552
Week 52 (12 Months)				
Mean (SE)	85.2 (2.9)	91.9 (3.5)	93.4 (3.1)	95.3 (5.5)
Median	83.3	89.05	92.05	94.0
Range	60.9, 115.0	66.7, 122.7	70.0, 116.2	57.3, 158.2
Change from Baseline				
Mean (SE)	0.9 (0.7)	-0.8(0.4)	0.1 (1.0)	-4.6 (2.3)
Median	0.45	-0.65	0.7	-2.55
Range	-4.6, 14.3	-4.1, 3.2	-8.6, 10.0	-43.2, 2.3
Mean Difference from Placebo	-	-1.8	-0.8	-5.5
p-value ‡	-	0.1837	0.2377	0.0069*

† Kruskal-Wallis test with Hochberg adjustment for multiple comparisons versus placebo.

‡ Two-way ANOVA with Hochberg adjustment for multiple comparisons versus placebo.

* Statistically significant difference compared to placebo

Table V

Body Weight: Changes from Baseline
Weights at Weeks 13, 26, and 52

Time Point/Body Weight (kg)	Placebo (N=89)	Pramlintide 30 µg TID (N=86)	Pramlintide 75 µg TID (N=83)	Pramlintide 150 µg TID (N=77)
Baseline				
Mean (SE)	90.6 (1.6)	90.3 (1.8)	93.2 (1.8)	94.3 (2.1)
Median	90.3	89.15	92.3	95.7
Range	59.5, 130.9	60.0, 140.0	51.8, 185.0	57.3, 158.1
Week 13 (3 Months)				
Mean (SE)	91.3 (1.6)	89.8 (1.8)	92.5 (1.9)	92.7 (2.1)
Median	90.0	89.3	92.3	92.3
Range	60.5, 132.9	57.7, 142.7	49.1, 166.8	56.4, 156.8
Change from Baseline				
Mean (SE)	0.6 (0.2)	-0.5 (0.3)	-0.6 (0.4)	-1.6 (0.3)
Median	0.5	-0.7	-0.4	-1.4
Range	-6.9, 8.7	-7.7, 10.5	-23.4, 9.5	-9.5, 2.7
Hodges-Lehman Estimator for Difference from Placebo p-value †	-	-1.1 0.0006*	-0.9 0.0066*	-2.0 0.0001*
Week 26 (6 months)				
Mean (SE)	91.5 (1.7)	89.7 (1.8)	92.3 (1.8)	92.6 (2.1)
Median	90.5	89.1	92.3	92.3
Range	58.6, 133.0	55.9, 140.9	46.4, 162.5	58.2, 156.4
Change from Baseline				
Mean (SE)	0.8 (0.3)	-0.6 (0.3)	-0.9 (0.5)	-1.7 (0.3)
Median	0.9	-0.45	0.0	-1.5
Range	-5.3, 8.3	-10.7, 11.4	-24.7, 9.0	-10.0, 3.2
Hodges-Lehman Estimator for Difference from Placebo p-value †	-	-1.3 0.0005*	-1.3 0.0029*	-2.3 0.0001*
Week 52 (12 Months)				
Mean (SE)	91.9 (1.7)	89.6 (1.9)	92.3 (1.9)	92.4 (2.1)
Median	90.0	89.05	92.7	92.7
Range	60.5, 136.6	55.9, 147.3	46.6, 170.8	56.4, 156.2
Change from Baseline				
Mean (SE)	1.2 (0.4)	-0.6 (0.4)	-0.9 (0.5)	-1.9 (0.7)
Median	0.9	-0.4	-0.3	-1.8
Range	-8.0, 20.5	-13.6, 11.9	-31.1, 10.0	-43.2, 7.3
Hodges-Lehman Estimator for Difference from Placebo p-value †	-	-1.6 0.0009*	-1.4 0.0106*	-2.7 0.0001*

† Kruskal-Wallis test with Hochberg adjustment for multiple comparisons versus placebo

* Statistically significant difference compared to placebo

Table VI

Body Weight: Changes from Baseline for Patients With Baseline BMI ≥ 27.0 kg/m² or < 27.0 kg/m²
Weights at Weeks 13, 26, and 52

BMI Subgroup/Body Weight (kg)	Placebo (N=91)	Pramlintide 30 μ g TID (N=88)	Pramlintide 75 μ g TID (N=97)	Pramlintide 150 μ g TID (N=80)
Baseline BMI ≥ 27.0 kg/m ²				
Change at Week 52				
N	67	67	80	62
Mean (SE)	0.7 (0.43)	-0.3 (0.52)	-0.7 (0.47)	-1.8 (0.80)
Range	-8.0, 10.0	-13.6, 11.9	-13.7, 10.0	-43.2, 7.3
Baseline BMI < 27.0 kg/m ²				
Change at Week 52				
N	24	21	17	18
Mean (SE)	2.4 (1.08)	-0.7 (0.56)	-1.7 (2.07)	-1.9 (0.71)
Range	-3.4, 20.5	-4.7, 6.4	-31.1, 9.0	-7.2, 6.5

Table VII

Body Weight: Changes from Baseline
Patients with HbA_{1c} $\geq 8.0\%$, Insulin Within $\pm 10\%$ of Baseline Weights at Weeks 13, 26, and 52

Time Point/Body Weight (kg)	Placebo (N=26)	Pramlintide 30 μ g TID (N=20)	Pramlintide 75 μ g TID (N=22)	Pramlintide 150 μ g TID (N=18)
Baseline				
Mean (SE)	84.3 (2.9)	82.7 (3.5)	93.3 (3.2)	99.8 (5.6)
Median	82.15	89.75	90.9	98.9
Range	61.4, 115.7	65.0, 119.5	65.0, 121.8	59.5, 158.1
Week 13 (3 Months)				
Mean (SE)	84.3 (2.8)	92.5 (3.6)	93.3 (3.3)	98.3 (5.7)
Median	81.5	88.85	91.6	97.4
Range	60.5, 112.3	65.9, 123.4	67.3, 121.8	57.7, 156.8
Change from Baseline				
Mean (SE)	0.0 (0.2)	-0.2 (0.5)	-0.0 (0.7)	-1.5 (0.4)
Median	0.45	-0.55	0	-1.55
Range	-3.4, 1.9	-4.6, 6.4	-5.9, 6.4	-3.9, 2.7
Hodges-Lehman Estimator for Difference from Placebo	-	-0.5	-0.4	-1.9
p-value †	-	0.2812	0.5827	0.0005*
Week 26 (6 months)				
Mean (SE)	84.8 (2.9)	92.4 (3.6)	93.1 (3.3)	98.1 (5.6)
Median	83.15	89.75	91.8	97.5
Range	60.9, 117.5	64.1, 123.6	71.8, 121.1	58.9, 156.4
Change from Baseline				
Mean (SE)	0.5 (0.3)	-0.3 (0.5)	-0.1 (0.8)	-1.8 (0.5)
Median	0.7	-0.45	0	-1.4
Range	-2.7, 4.7	-3.7, 4.1	-6.8, 7.3	-5.4, 2.0
Hodges-Lehman Estimator for Difference from Placebo	-	-0.8	-0.6	-2.2
p-value †	-	0.8903	0.3616	0.0552
Week 52 (12 Months)				
Mean (SE)	85.2 (2.9)	91.9 (3.5)	93.4 (3.1)	95.3 (5.5)
Median	83.3	89.05	92.05	94.0
Range	60.9, 115.0	66.7, 122.7	70.0, 116.2	57.3, 158.2
Change from Baseline				
Mean (SE)	0.9 (0.7)	-0.8 (0.4)	0.1 (1.0)	-4.6 (2.3)
Median	0.45	-0.65	0.7	-2.55
Range	-4.6, 14.3	-4.1, 3.2	-8.6, 10.0	-43.2, 2.3
Mean Difference from Placebo	-	-1.8	-0.8	-5.5
p-value ‡	-	0.1837	0.2377	0.0069*

† Kruskal-Wallis test with Hochberg adjustment for multiple comparisons versus placebo.

‡ Two-way ANOVA with Hochberg adjustment for multiple comparisons versus placebo.

* Statistically significant difference compared to placebo

EXAMPLE 4**Preparation of ^{25,28,29}Pro-h-Amylin**

5 Solid phase synthesis of ^{25,28,29}Pro-h-amylin using methylbenzhydrylamine anchor-bond resin and N^α-Boc/benzyl-side chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide]amylin-MBHA-resin was obtained by treatment of Ac₂m-protected cysteines with
10 thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The ^{25,28,29}Pro-h-amylin was purified by preparative reversed-phase HPLC. The peptide was
15 found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: (M+H)⁺=3,949.

EXAMPLE 5**Preparation of ¹⁸Arg^{25,28,29}Pro-h-Amylin**

20 Solid phase synthesis of ¹⁸Arg^{25,28,29}Pro-h-amylin using methylbenzhydrylamine anchor-bond resin and N^α-Boc/benzyl-side chain protection was carried out by
25 standard peptide synthesis methods. The 2,7-[disulfide]amylin-MBHA-resin was obtained by treatment of Ac₂m-protected cysteines with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the
30 resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole.

The $^{18}\text{Arg}^{25,28,29}\text{Pro-h-amylin}$ was purified by preparative reversed-phase HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: $(\text{M}+\text{H})^+=3,971$.

EXAMPLE 6

Preparation of $^{18}\text{Arg}^{25,28}\text{Pro-h-Amylin}$

Solid phase synthesis of $^{18}\text{Arg}^{25,28}\text{Pro-h-amylin}$ using methylbenzhydrylamine anchor-bond resin and N^a-Boc/benzyl-side chain protection was carried out by standard peptide synthesis methods. The 2,7-[disulfide]amylin-MBHA-resin was obtained by treatment of Ac^m-protected cysteines with thallium (III) trifluoroacetate in trifluoroacetic acid. After cyclization was achieved the resin and side chain protecting groups were cleaved with liquid HF in the presence of dimethylsulfide and anisole. The $^{18}\text{Arg}^{25,28}\text{Pro-h-amylin}$ was purified by preparative reversed-phase HPLC. The peptide was found to be homogeneous by analytical HPLC and capillary electrophoresis and the structure confirmed by amino acid analysis and sequence analysis. The product gave the desired mass ion. FAB mass spec: $(\text{M}+\text{H})^+=3,959$.

EXAMPLE 7Receptor Binding Assay

Evaluation of the binding of compounds to amylin
5 receptors was carried out as follows. ^{125}I -rat amylin
(Bolton-Hunter labeled at the N-terminal lysine) was
purchased from Amersham Corporation (Arlington Heights, IL).
Specific activities at time of use ranged from 1950 to 2000
Ci/mmol. Unlabeled peptides were obtained from BACHEM Inc.
10 (Torrance, CA) and Peninsula Laboratories (Belmont, CA).

Male Sprague-Dawley rats (200-250) grams were
sacrificed by decapitation. Brains were removed to cold
phosphate-buffered saline (PBS). From the ventral surface,
cuts were made rostral to the hypothalamus, bounded laterally
15 by the olfactory tracts and extending at a 45° angle medially
from these tracts. This basal forebrain tissue, containing
the nucleus accumbens and surrounding regions, was weighed
and homogenized in ice-cold 20 mM HEPES buffer (20 mM HEPES
acid, pH adjusted to 7.4 with NaOH at 23°C). Membranes were
20 washed three times in fresh buffer by centrifugation for 15
minutes at $48,000 \times g$. The final membrane pellet was
resuspended in 20 mM HEPES buffer containing 0.2 mM
phenylmethylsulfonyl fluoride (PMSF).

To measure ^{125}I -amylin binding, membranes from 4 mg
25 original wet weight of tissue were incubated with ^{125}I -amylin
at 12-16 pM in 20 mM HEPES buffer containing 0.5 mg/ml
bacitracin, 0.5 mg/ml bovine serum albumin, and 0.2 mM PMSF.
Solutions were incubated for 60 minutes at 23°C . Incubations
were terminated by filtration through GF/B glass fiber
30 filters (Whatman Inc., Clifton, NJ) which had been presoaked

for 4 hours in 0.3% polyethyleneimine in order to reduce nonspecific binding of radiolabeled peptides. Filters were washed immediately before filtration with 5 ml cold PBS, and immediately after filtration with 15 ml cold PBS. Filters were removed and radioactivity assessed in a gamma-counter at a counting efficiency of 77%. Competition curves were generated by measuring binding in the presence of 10^{-12} to 10^{-6} M unlabeled test compound and were analyzed by nonlinear regression using a 4-parameter logistic equation (Inplot program; GraphPAD Software, San Diego).

In this assay, purified human amylin binds to its receptor at a measured IC_{50} of about 50 pM. Results for test compounds are set forth in Table VIII, showing that each of the compounds has significant receptor binding activity.

EXAMPLE 8

Soleus Muscle Assay

Determination of amylin agonist activity of compounds was carried out using the soleus muscle assay as follows. Male Harlan Sprague-Dawley rats of approximately 200g mass were used in order to maintain mass of the split soleus muscle less than 40mg. The animals were fasted for 4 hours prior to sacrifice by decapitation. The skin was stripped from the lower limb which was then pinned out on corkboard. The tendo achilles was cut just above os calcis and *m. gastrocnemius* reflected out from the posterior aspect of the tibia. *M. soleus*, a small 15-20mm long, 0.5mm thick flat muscle on the bone surface of *m. gastrocnemius* was then stripped clear and the perimysium cleaned off using fine

scissors and forceps. *M. soleus* was then split into equal parts using a blade passed antero-posteriorly through the belly of the muscle to obtain a total of 4 muscle strips from each animal. After dissecting the muscle from the animal, it was kept for a short period in physiological saline. It was not necessary that the muscle be held under tension as this had no demonstrable effects on radioglucose incorporation into glycogen.

Muscles were added to 50mL Erlenmeyer flasks containing 10mL of a pregassed Krebs-Ringer bicarbonate buffer containing (each liter) NaCl 118.5 mmol (6.93g), KCl 5.94 mmol (443mg), CaCl₂ 2.54 mmol (282mg), MgSO₄ 1.19 mmol (143mg), KH₂PO₄ 1.19 mmol (162mg), NaHCO₃ 25 mmol (2.1g), 5.5mmol glucose (1g) and recombinant human insulin (Humulin-R, Eli Lilly, IN) and the test compound, as detailed below. pH at 37°C was verified as being between 7.1 and 7.4. Muscles were assigned to different flasks so that the 4 muscle pieces from each animal were evenly distributed among the different assay conditions. The incubation media were gassed by gently blowing carbogen (95% O₂, 5% CO₂) over the surface while being continuously agitated at 37°C in an oscillating water bath. After a half-hour "preincubation" period, 0.5μCi of U-¹⁴C-glucose was added to each flask which was incubated for a further 60 minutes. Each muscle piece was then rapidly removed, blotted and frozen in liquid N₂, weighed and stored for subsequent determination of ¹⁴C-glycogen.

¹⁴C-glycogen determination was performed in a 7mL scintillation vial. Each frozen muscle specimen was placed in a vial and digested in 1mL 60% potassium hydroxide at 70°C

for 45 minutes under continuous agitation. Dissolved glycogen was precipitated out onto the vial by the addition of 3mL absolute ethanol and overnight cooling at -20°C. The supernatant was gently aspirated, the glycogen washed again with ethanol, aspirated and the precipitate dried under vacuum. All ethanol is evaporated to avoid quenching during scintillation counting. The remaining glycogen was redissolved in 1mL water and 4mL scintillation fluid and counted for ^{14}C .

The rate of glucose incorporation into glycogen (expressed in $\mu\text{mol/g/hr}$) was obtained from the specific activity of ^{14}C -glucose in the 5.5mM glucose of the incubation medium, and the total ^{14}C counts remaining in the glycogen extracted from each muscle. Dose/response curves were fitted to a 4-parameter logistic model using a least-squares iterative routine (ALLFIT, v2.7, NIH, MD) to derive EC_{50} 's. Since EC_{50} is log-normally distributed, it is expressed \pm standard error of the logarithm. Pairwise comparisons were performed using t-test based routines of SYSTAT (Wilkinson, "SYSTAT: the system for statistics," SYSTAT Inc., Evanston IL (1989)).

Dose response curves were generated with muscles added to media containing 7.1nM (1000 $\mu\text{U/mL}$) insulin and each test compound added at final (nominal) concentrations of 0, 1, 3, 10, 30, 100, 300 and 1000nM. Each assay also contained internal positive controls consisting of a single batch of archived rat amylin, lyophilized and stored at -70°C.

Human amylin is a known hyperglycemic peptide, and EC_{50} measurements of amylin preparations in the soleus muscle assay range typically from about 1-10 nM, although some

commercial preparations which are less than 90% pure have higher EC_{50} 's due to the presence of contaminants that result in a lower measured activity. Results for test compounds are set forth in Table VIII.

5

TABLE VIII

	Muscle	Receptor Binding	Soleus
	EC_{50} (nM)	Assay IC_{50} (pM)	Assay
10	1) 25 Pro 36 Val 28,29 Pro-h-Amylin	18.0	4.68
	2) 2,7 Cyclo-[1 Asp, 7 Lys]-h-Amylin	310.0	6.62
15	3) 2,37 h-Amylin	236.0	1.63
	4) 1 Ala-h-Amylin	148.0	12.78
	5) 1 Ser-h-Amylin	33.0	8.70
	6) 25,28 Pro-h-Amylin	26.0	13.20
	7) des- 1 Lys 25,28 Pro-h-Amylin	85.0	7.70
20	8) 18 Arg 25,28 Pro-h-Amylin	32.0	2.83
	9) des- 1 Lys 18 Arg 25,28 Pro-h-Amylin	82.0	3.77
	10) 18 Arg 25,28,29 Pro-h-Amylin	21.0	1.25
	11) des- 1 Lys 18 Arg 25,28,29 Pro-h-Amylin	21.0	1.86
	12) 25,28,29 Pro-h-Amylin	10.0	3.71
25	13) des- 1 Lys 25,28,29 Pro-h-Amylin	14.0	4.15

EXAMPLE 9PHENOL RED GASTRIC EMPTYING ASSAY

Gastric emptying was measured using a modification
5 (Plourde *et al.*, Life Sci. 53:857-862 (1993)) of the original
method of Scarpignato *et al.* (Arch. Int. Pharmacodyn. Ther.
246:286-295 (1980)). Briefly, conscious rats received by
gavage. 1.5 mL of an acoloric gel containing 1.5% methyl
cellulose (M-0262, Sigma Chemical Co., St. Louis, MO) and
10 0.05% phenol red indicator. Twenty minutes after gavage,
rats were anesthetized using 5% halothane, the stomach
exposed and clamped at the pyloric and lower esophageal
sphincters using artery forceps, removed and opened into an
alkaline solution which was made up to a fixed volume.
15 Stomach content was derived from the intensity of the phenol
red in the alkaline solution, measured by absorbance at a
wavelength of 560 nm. In most experiments, the stomach was
clear. In other experiments, particulate gastric contents
were centrifuged to clear the solution for absorbance
20 measurements. Where the diluted gastric contents remained
turbid, the spectroscopic absorbance due to phenol red was
derived as the difference between that present in alkaline vs
acetified diluent. In separate experiments on 7 rats, the
stomach and small intestine were both excised and opened into
25 an alkaline solution. The quantity of phenol red that could
be recovered from the upper gastrointestinal tract within 29
minutes of gavage was $89 \pm 4\%$; dye which appeared to bind
irrecoverably to the gut luminal surface may have accounted
for the balance. To compensate for this small loss, percent
30 of stomach contents remaining after 20 minutes were expressed

as a fraction of the gastric contents recovered from control rats sacrificed immediately after gavage in the same experiment. Percent gastric emptying contents remaining = (absorbance at 20 min)/(absorbance at 0 min). Dose response curves for gastric emptying were fitted to a 4-parameter logistic model using a least-squares iterative routine (ALLFIT, v2.7, NIH, Bethesda, MD) to derive ED_{50} s. Since ED_{50} is log-normally distributed, it is expressed \pm standard error of the logarithm. Pairwise comparisons were performed using one-way analysis of variance and the Student-Newman-Keuls multiple comparisons test (Instat v2.0, GraphPad Software, San Diego, CA) using $P < 0.05$ as the level of significance.

In dose response studies, rat amylin (Bachem, Torrance, CA) dissolved in 0.15M saline, was administered as a 0.1 mL subcutaneous bolus in doses of 0, 0.01, 0.1, 1, 10 or 100 μ g 5 minutes before gavage in Harlan Sprague Dawley (non-diabetic) rats fasted 20 hours and diabetic BB rats fasted 6 hours. When subcutaneous amylin injections were given 5 minutes before gavage with phenol red indicator, there was a dose-dependent suppression of gastric emptying (data not shown). Suppression of gastric emptying was complete in normal HSD rats administered 1 μ g of amylin, and in diabetic rats administered 10 μ g ($P = 0.22, 0.14$). The ED_{50} for inhibition of gastric emptying in normal rats was 0.43 μ g (0.60 nmol/kg) \pm 0.19 log units, and was 2.2 μ g (2.3 nmol/kg) \pm 0.18 log units in diabetic rats.

EXAMPLE 10TRITIATED GLUCOSE GASTRIC EMPTYING ASSAY

Conscious, non-fasted, Harlan Sprague Dawley rats were restrained by the tail, the tip of which was anesthetized using 2% lidocaine. Tritium in plasma separated from tail blood collected 0, 15, 30, 60, 90 and 120 minutes after gavage was detected in a beta counter. Rats were injected subcutaneously with 0.1 mL saline containing 0, 0.1, 0.3, 1, 10 or 100 μ g of rat amylin 1 minute before gavage (n=8,7,5,5,5, respectively). After gavage of saline pre-injected rats with tritiated glucose, plasma tritium increased rapidly (t $\frac{1}{2}$ of about 8 minutes) to an asymptote that slowly declined. Subcutaneous injection with amylin dose-dependently slowed and/or delayed the absorption of the label. Plasma tritium activity was integrated over 30 minutes to obtain the areas under the curve plotted as a function of amylin dose. The ED₅₀ derived from the logistic fit was 0.35 μ g of amylin.